Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma.

[1]  H. Nevanlinna,et al.  Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Geng,et al.  Correlation between chemosensitivity to anticancer drugs and Bcl-2 expression in gastric cancer. , 2013, International journal of clinical and experimental pathology.

[3]  G. Liang,et al.  Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues , 2013, World Journal of Surgical Oncology.

[4]  Chen-hai Liu,et al.  NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T gene polymorphism association with digestive tract cancer: a meta-analysis. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[5]  Y. Zhang,et al.  Meta-analysis demonstrates that the NAD(P)H: quinone oxidoreductase 1 (NQO1) gene 609 C>T polymorphism is associated with increased gastric cancer risk in Asians. , 2012, Genetics and molecular research : GMR.

[6]  Xian-Jin Xie,et al.  Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy , 2011, Clinical Cancer Research.

[7]  Gang Li,et al.  The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. , 2010, Free radical biology & medicine.

[8]  K. Shroyer,et al.  NQO1 Expression in Pancreatic Cancer and Its Potential Use as a Biomarker , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[9]  B. Lyn-Cook,et al.  Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas , 2006, Cell Biology and Toxicology.

[10]  M. Tsao,et al.  Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer , 2005, Molecular carcinogenesis.

[11]  N. Hamajima,et al.  Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. , 2005, Gynecologic oncology.

[12]  M. Manns,et al.  Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. , 2002, Molecular pharmacology.

[13]  D. Ross,et al.  Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. , 2000, Free radical biology & medicine.

[14]  A. Tomida,et al.  Immunological Quantitation of DT‐Diaphorase in Carcinoma Cell Lines and Clinical Colon Cancers: Advanced Tumors Express Greater Levels of DT‐Diaphorase , 1998, Japanese journal of cancer research : Gann.

[15]  P. Workman,et al.  DT-diaphorase and cancer chemotherapy. , 1992, Biochemical pharmacology.